Equities

CareDx Inc

CareDx Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)14.19
  • Today's Change-0.42 / -2.87%
  • Shares traded731.30k
  • 1 Year change+81.69%
  • Beta1.7699
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.

  • Revenue in USD (TTM)275.11m
  • Net income in USD-183.19m
  • Incorporated1998
  • Employees635.00
  • Location
    CareDx Inc8000 Marina Blvd, 4Th FloorBRISBANE 94005United StatesUSA
  • Phone+1 (415) 287-2300
  • Fax+1 (302) 636-5454
  • Websitehttps://www.caredx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CDNA:NMQ since
announced
Transaction
value
MediGO IncDeal completed25 Jul 202325 Jul 2023Deal completed36.31%--
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ModivCare Inc2.77bn-222.80m375.17m21.20k--2.76--0.1353-15.72-15.72195.509.551.50--8.59130,816.70-11.89-1.36-16.49-1.8315.7117.58-7.94-0.9619--0.39090.8906--9.8514.71-542.83--19.27--
Talkspace Inc162.13m-11.89m390.17m472.00--3.26--2.41-0.0716-0.07160.97210.70521.15--13.80343,485.20-8.40---9.68--48.95---7.33------0.00--25.49--75.92------
Enhabit Inc1.04bn-83.00m441.37m10.80k--0.6571--0.4229-1.67-1.6720.8413.390.7022--6.3196,629.63-5.47---6.20--48.52---7.79----0.60310.438---2.32---99.26------
Aveanna Healthcare Holdings Inc1.92bn-113.70m477.10m3.50k------0.2486-0.5993-0.599310.08-0.69731.14--7.45548,414.00-6.74---8.69--31.0931.12-5.92-12.71--1.841.10--6.028.6279.68---20.76--
Accolade Inc414.29m-99.81m484.25m2.40k--1.08--1.17-1.34-1.345.515.710.4899--15.23172,621.70-11.80-24.80-13.63-29.0446.5245.56-24.09-56.43----0.3188--14.0934.3078.29--31.97--
Community Health Systems Inc12.52bn-123.00m491.94m61.00k----0.94790.0393-0.9399-0.939995.71-10.280.86255.865.91205,295.100.20660.75660.25460.938184.2483.690.23960.93451.331.211.08--2.28-2.47-389.13---2.39--
QDM International Inc6.53m1.69m583.13m3.0052.56179.05340.2989.260.0380.0380.02960.01121.81--148.49--46.82--127.17--38.10--25.81----1,761.140.2722--1,542.96--111.78------
Pediatrix Medical Group Inc2.00bn-70.58m609.23m2.90k--0.7104--0.3048-0.8595-0.859524.1310.190.8907--7.11689,218.30-3.150.8579-3.570.9945-----3.531.52--4.420.45320.001.152.97-196.55--14.25--
Diversified Healthcare Trust1.44bn-327.17m677.91m0.00--0.3015--0.4724-1.37-1.376.009.350.2606-------5.62-1.04-5.67-1.0616.6824.43-21.55-4.93---0.41420.5579--9.874.77-1,761.11--0.1461-51.94
Pennant Group Inc575.34m16.44m682.34m5.79k41.834.6330.801.190.54290.542919.014.901.06--9.4399,351.063.121.813.672.1420.3521.622.951.92--4.220.33650.0015.1413.76101.40-3.1314.07--
InnovAge Holding Corp741.33m-30.82m690.82m2.10k--2.46--0.9319-0.227-0.2275.462.071.35--20.98353,013.30-6.01---8.23--16.73---4.45-----4.070.2125---1.51---523.72------
CareDx Inc275.11m-183.19m739.07m635.00--2.87--2.69-3.43-3.435.164.950.56115.354.61433,245.70-37.36-17.54-43.69-20.8562.9465.50-66.59-27.784.03--0.00---12.8929.63-148.37--5.01--
Data as of Jun 14 2024. Currency figures normalised to CareDx Inc's reporting currency: US Dollar USD

Institutional shareholders

62.43%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Mar 20245.86m11.26%
BlackRock Fund Advisorsas of 31 Mar 20244.38m8.40%
The Vanguard Group, Inc.as of 31 Mar 20244.26m8.17%
SSgA Funds Management, Inc.as of 31 Mar 20244.20m8.06%
Bellevue Asset Management AGas of 31 Mar 20243.93m7.55%
Nikko Asset Management Americas, Inc.as of 31 Mar 20242.75m5.28%
Gagnon Securities LLCas of 31 Mar 20242.25m4.31%
D. E. Shaw & Co. LPas of 31 Mar 20242.02m3.88%
Dimensional Fund Advisors LPas of 31 Mar 20241.45m2.78%
Renaissance Technologies LLCas of 31 Mar 20241.42m2.74%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.